Period:
Draw Mode:
| Volume | 30,715 |
|
|||||
| News | - | ||||||
| Day High | 0.725892 | Low High |
|||||
| Day Low | 0.67 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Iterum Therapeutics PLC | ITRM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03079 | 4.43% | 0.725892 | 13:42:16 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.69 | 0.67 | 0.725892 | 0.6951 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 90 | 30,715 | $ 0.7134063 | $ 21,912 | - | 0.601098 - 2.0499 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:42:16 | 100 | $ 0.725892 | USD |
Iterum Therapeutics PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 9.47M | 13.04M | - | 503k | -43.67M | -3.35 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Iterum Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITRM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7382 | 0.759787 | 0.645 | 0.6828007 | 14,443 | -0.01231 | -1.67% |
| 1 Month | 0.88 | 0.90 | 0.645 | 0.7719527 | 18,706 | -0.15411 | -17.51% |
| 3 Months | 1.10 | 1.26 | 0.645 | 1.00 | 38,495 | -0.37411 | -34.01% |
| 6 Months | 0.9589 | 1.36 | 0.645 | 1.08 | 45,292 | -0.23301 | -24.3% |
| 1 Year | 1.80 | 2.0499 | 0.601098 | 1.19 | 129,459 | -1.07 | -59.67% |
| 3 Years | 0.6354 | 3.1305 | 0.175 | 1.32 | 5,543,958 | 0.09049 | 14.24% |
| 5 Years | 6.70 | 9.3007 | 0.175 | 1.34 | 3,414,471 | -5.97 | -89.17% |
Iterum Therapeutics Description
| Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. |